Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.